JSKN-022

N/A

Report date: 2025/10/11 13:39:38
First In Class

Base Information

Drug NameJSKN-022
Drug Alias NameJSKN022JSKN-022
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > T01 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker +[6] 
Mechanisms of ActionDNA topoisomerase I inhibitorsProgrammed death-ligand 1 antagonistsIntegrin beta-6 binders +[4] 
TargetsDNA topoisomerase IProgrammed death-ligand 1Integrin beta-6 +[4] 
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAlphamab Oncology
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesJiangsu Alphamab Biopharmaceuticals Co Ltd
Inactive CompaniesAlphamab Oncology
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A